EIT Health partners with PSCC to drive innovation

04 Jul 2023 | Network Updates | Update from EIT Health
These updates are republished press releases and communications from members of the Science|Business Network

We are proud to announce a new collaboration with the Paris Saclay Cancer Cluster (PSCC). Through this collaboration, start-ups within the PSCC will gain access to our network of over 130 European partners, tapping into their proven expertise in fundraising and cancer innovation. Additionally, they will benefit from the Venture Centre of Excellence (VCoE) programme, courtesy of Sanofi’s membership, an innovative global healthcare company – one of PSCC’s founding members.

Awarded the Bio-cluster label under the France 2030 NextGenerationEU programme, the PSCC is the first of its kind in France. It aims to drive innovation in oncology to make it more predictive, precise, and efficient by serving as a single gateway for innovative projects. The cluster brings together the actors of oncology innovation to develop solutions by offering services, including expertise, cutting-edge technology platforms, access to patient samples, financing, and spaces.

Jean-Marc Bourez, CEO of EIT Health, said: “This collaboration marks a major leap in our mission to accelerate oncology innovation. By harnessing the collective strengths of our networks, we empower start-ups to thrive in a diverse and dynamic European ecosystem. Together with PSCC, we are committed to shaping the healthcare innovation landscape, nurturing talent, and scaling transformative solutions. With a shared dedication to improving patients’ lives, we anticipate remarkable breakthroughs to emerge from this partnership.

This partnership solidifies PSCC’s position as a key European hub for start-ups and investors, fast-tracking innovations from the research stage to the market. It also links to a broad network of Life Science investors across Europe, potentially releasing over €2 billion in investment for PSCC-associated start-ups.

Eric Vivier, President of the PSCC, commented: “The PSCC is very pleased to announce this partnership that supports its objective of accelerating innovation in oncology. This partnership with EIT Health will open doors for PSCC-supported projects at the European level, enabling them to benefit from the European ecosystem and European funding.

The Gustave Roussy Institute (IGR), a renowned cancer treatment centre, and Sanofi have been longstanding partners of EIT Health and are also founding members of PSCC. Over the past five years, we have provided funding for more than 160 projects, including I4PCM and EHR2EDC, in collaboration with IGR and Sanofi, respectively. These projects have facilitated the collection of clinical data from electronic health records, leading to improved efficiency in medical research and faster access to innovative treatments.

Christian Deleuze, Head of Innovation and Oncology Biocluster, Sanofi, commented: “Sanofi has a responsibility to contribute to the dynamism of innovation and entrepreneurship ecosystems in France and Europe. Our membership in the Venture Centre of Excellence program is a fine illustration of this. It will support the initiative we co-initiated two years ago by contributing to the invention of the PSCC. Partnerships between the public and private sectors are more essential than ever to address healthcare challenges and accelerate the discovery and development of tomorrow’s new treatments”.

Since its inception, we have played a pivotal role in the rise of over 1,200 European start-ups, including the gynaecological cancer diagnostics firm, MiMARK. With a €6M backing, MiMARK, which has been involved in the 2020 WildCard Programme, has revolutionised women’s healthcare with its innovative diagnostic test, WomEC, detecting endometrial cancer through biomarkers present in uterine fluids.

Learn more about our programmes.

This article was first published on 30 June by EIT Health.

Never miss an update from Science|Business:   Newsletter sign-up